Advanced glycation end products (AGEs), a heterogeneous group of compounds formed by nonenzymatic glycation reactions between reducing sugars and amino acids, lipids, or DNA, are formed not only in the presence of hyperglycemia, but also in diseases associated with high levels of oxidative stress, such as CKD. In chronic renal failure, higher circulating AGE levels result from increased formation and decreased renal clearance. Interactions between AGEs and their receptors, including advanced glycation end product-specific receptor (RAGE), trigger various intracellular events, such as oxidative stress and inflammation, leading to cardiovascular complications. Although patients with CKD have a higher burden of cardiovascular disease, the relationship between AGEs and cardiovascular disease in patients with CKD is not fully characterized. In this paper, we review the various deleterious effects of AGEs in CKD that lead to cardiovascular complications and the role of these AGEs in diabetic nephropathy. We also discuss potential pharmacologic approaches to circumvent these deleterious effects by reducing exogenous and endogenous sources of AGEs, increasing the breakdown of existing AGEs, or inhibiting AGE-induced inflammation. Finally, we speculate on preventive and therapeutic strategies that focus on the AGE-RAGE axis to prevent vascular complications in patients with CKD.
Advanced glycation end products (AGEs) constitute a heterogeneous group of compounds derived from the nonenzymatic glycation of proteins, lipids, and nuclear acids through a complex sequence of reactions referred to as the Maillard reaction. 1,2
Generation of AGEs
Protein glycation is initiated by a nucleophilic addition reaction between a free amino group from a protein and a carbonyl group from a reducing sugar, with the formation of an unstable, freely reversible Schiff base. This base can be rearranged to form a more stable intermediate called an Amadori product, which in the presence of a transition metal, is oxidized toyield the final AGE (Figure 1 ) (reviewed in ref.
3). AGEs can also be formed by autoxidation of glucose and oxidative stress. Humans are exposed to exogenous sources of AGE (diet 4 and cigarette smoke 5 ) and endogenous sources of AGE when the organism is exposed to high levels of glucose, such as in diabetes. 6 AGE precursors include the 1,2-dicarbonyl compounds glyoxal and methylglyoxal (MG), a highly reactive dicarbonyl compound. 7 At least 20 different types of AGE have been described: N-carboxymethyllysine (CML), pentosidine, and hydroimidazolone are among the best characterized, are relatively nonreactive, and serve as markers of AGE accumulation in several tissues. 8, 9 AGEs can be degraded by enzymes, such as glyoxalase I (Glo-1) and II (Glo-2). 10 Glo-1 detoxifies reactive a-oxoaldehyde, removing deleterious species, such as MG. 11 AGEs can also be modified by innate defense machineries, such as lysozyme, which sequesters AGEs and accelerates their renal excretion in vivo, 12 and receptor-dependent uptake and degradation. 13 reducing AGE levels in the intracellular and extracellular spaces, resulting in antioxidant properties. 15, 16 Advanced glycation end product-specific receptor (RAGE), another well characterized receptor for AGEs, is a multiligand transmembrane cell surface receptor that belongs to the Ig protein superfamily 17, 18 and binds many ligands, including AGEs. 19 In the absence of disease, RAGE is usually expressed at very low levels in various cell types (smooth muscle cells, macrophages, and endothelial cells). In several diseases, such as diabetes and autoimmune/ inflammatory diseases, RAGE expression is elevated, 20 whereas AGER1 levels are decreased, resulting in suppression of the antioxidant defense system and increased levels of pro-oxidant mechanisms. The soluble truncated form of RAGE lacks the full-length transmembrane domain of the receptor. Soluble advanced glycation end product-specific receptor (sRAGE) can be produced by alternative splicing (endogenous secretory advanced glycation end product-specific receptor [esRAGE] ) or proteolytic cleavage mediated by metalloproteinase (sRAGE). It is consequently released into the extracellular space, where it can sequester AGEs. High sRAGE levels are associated with an increased incidence of CKD before but not after adjustment for baseline kidney function, 21 suggesting that either circulating sRAGE levels are directly affected by an impaired kidney filtration as assessed by GFR or inversely, circulating sRAGE directly affects kidney function. Additional studies are needed to elucidate the mechanisms of the association between sRAGE and kidney disease.
Signaling through RAGE RAGE was first identified as a signal transduction receptor for AGEs linked to proteins or lipids. 22 RAGE can also interact with advanced oxidation protein products, supporting the hypothesis that ligands generated by oxidative stress may signal through RAGE. 23 Full-length RAGE contains a single transmembrane region and a short intracellular domain. Upon binding to RAGE, AGEs activate several signaling pathways, including NF-kB, mitogen-activated protein kinases, and Jun N-terminal kinase, which in turn, regulate the transcription of proteins, such as adhesion molecules and proinflammatory chemokines. Signaling through full-length RAGE is known to be essential for both physiologic and pathologic processes. 8,24-27 sRAGE acts as a decoy for RAGE ligands and modulates activation or signaling through RAGE. 28 
PATHOPHYSIOLOGIC EFFECTS OF AGES

Mechanisms
Accumulation of AGEs in patients with CKD has been shown to result from inflammation, oxidative stress, and diet ( Figure 2) . 29, 30 AGEs are proinflammatory and pro-oxidative compounds that play a role in the high prevalence of endothelial dysfunction and subsequent cardiovascular disease (CVD) in patients with CKD. 31 Oxidative Stress The oxidative stress induced by reactive oxygen species (ROS) is associated with atherosclerosis and cardiovascular morbidity in patients with CKD. 32 AGEs increase the levels of ROS 33 through activation of NADPH oxidase 34 and mitochondrial pathways in both a receptor-dependent manner (i.e., through RAGE) 35 and a receptor-independent manner. In patients with type 2 diabetes mellitus, circulating AGE levels are correlated with RAGE mRNA expression and oxidative markers, such as protein carbonyl formation, advanced oxidation protein product generation, and lipid peroxidation. 36 Reciprocally, high levels of ROS lead to increased levels of AGEs, 37 because another cause of AGE formation in uremia is the increased oxidative stress generated by an imbalance between oxidized glutathione and GSH levels as well as changes in antioxidant systems, such as superoxide dismutase (SOD)/peroxidase. 5 In fact, oxidative stress is closely linked to glycation, because GSH depletion also decreases the in situ activity of Glo-1, thereby increasing glyoxal and MG concentrations. 10 Interestingly, AGER1 is downregulated by elevated AGE levels. 38 Furthermore, AGEs have been shown to increase the oxidation of LDLs 39 -a key stage in the development of atherosclerosis. 40 Glycated LDLs are, therefore, more susceptible to oxidation, 41 are less effectively cleared from the circulation, and also, promote the formation of antibodies that bind AGEs localized in the vessel wall, which amplifies the development of vascular inflammation and atherosclerosis. 42 Overexpression of Glo-1 in an animal model has been shown to have beneficial vascular effects, decrease ROS, 43 and protect against formation of atherogenic LDL.
Numerous studies have shown that the nuclear factor erythroid 2-related factor (Nrf2) plays an important role in the antioxidant response. Under basal conditions, Nrf2 is associated in the cytoplasm with the repressor kelch like ECHassociated protein1 (Keap1), which promotes its ubiquitination for degradation. 44 However, in response to oxidative stress, Nrf2 is released from Keap1 and translocates to the nucleus to induce the expression of genes encoding antioxidant and detoxifying molecules by binding to the antioxidant response element region of their promoter. Moreover, it has been shown that targeting Nrf2 ameliorates oxidative stress. 45 Several studies have shown that some Nrf2 target antioxidant genes (SOD and glutathione peroxidase) are decreased in animal models of CKD 46 and patients with CKD, 47 which may consequently aggravate oxidative stress and inflammation. MG induces oxidative stress partly by negatively affecting Nrf2. 48 Interestingly, one of the targets of the Nrf2/ Keap system is Glo-1. In Nrf2 2/2 mice, Glo-1 mRNA is decreased, whereas MG urine excretion is increased. 49 Transcriptional control of Glo-1 by Nrf2, therefore, provides protection against dicarbonyl glycation.
Inflammation
AGEs have been shown to amplify inflammatory responses in patients with CKD 50,51 through RAGE, 52,53 because the RAGE-AGE interaction activates the redoxsensitive transcription factor NF-kB, which leads to gene expression and the release of proinflammatory molecules, such as IL1a, IL-6, and TNF-a. 54, 55 The in vitro use of human recombinant lysozyme significantly reduced AGE-induced IL-6 mRNA. 56 It has recently been shown that targeting Nrf2 ameliorates inflammation by inhibiting the NF-kB pathway 45 and probably, increasing Glo-1, which detoxifies reactive oxoaldehydes, such as MG. RAGE expression by activated endothelium also promotes leukocyte recruitment. 57-60 Moreover, AGEs delay spontaneous apoptosis of monocytes and consequently, contribute to the The main deleterious effects of AGEs in the cardiovascular system are described below.
Endothelial Dysfunction
Endothelial dysfunction, an early marker of atherosclerosis, 77 is predictive of the occurrence of cardiovascular events. In CKD, endothelial dysfunction begins early in the course of the disease independently of traditional cardiovascular risk factors. 78 Plasma levels of endothelial cell activation markers are elevated in advanced CKD, and exposure of the endothelium to uremic plasma increases soluble vascular cell adhesion molecule-1 (VCAM-1) expression. 63 AGE-RAGE-induced oxidative stress is central to VCAM-1 induction, because anti-RAGE antibodies, sRAGE, and N-acetylcysteine inhibit VCAM-1 expression. 79 It has recently been shown that chronic CML ingestion induced RAGEdependent endothelial dysfunction in mice. 80 Furthermore, Glo-1 overexpression decreases endothelial dysfunction in a diabetic rat model. 81 In patients with CKD, endothelial dysfunction results from increased endothelial injury and decreased endothelial repair 82 caused by a decreased endothelial progenitor cell (EPC) count. [83] [84] [85] [86] [87] [88] [89] Furthermore, circulating EPC levels in patients with ESRD are negatively correlated with skin autofluorescence (a marker of tissuebound AGEs) but not with serum pentosidine levels. 89, 90 Recent studies have shown that AGEs impair EPC survival, differentiation, migration, and function. [91] [92] [93] One of the endothelium's most important functions is the synthesis and release of endothelium-derived relaxing factors, such as nitric oxide (NO) and prostaglandin I2 (PGI2). Patients with CKD display impaired endotheliumdependent vasodilation. 94 AGEs have been shown to impair NO production partly by downregulating NO synthase 34,39,95 through increased mRNA degradation. 96 In vitro studies show that sera from patients with CKD suppress endothelial NO synthase activity in cultured vascular endothelial cells. 97, 98 This inhibition of endothelial NO synthase activity is mediated by RAGE activation of peripheral mononuclear cells in patients with CKD. 31 AGEs also inhibit NO by increasing NADPH oxidase expression, establishing a link between RAGE and chronic endothelial dysfunction. 34,39,95 PGI2 has also been shown to be decreased by AGEs, such as glycated albumin in cultured microvascular endothelial cells. 99 Endothelial dysfunction is defined as an imbalance between vasodilating and vasoconstricting substances produced by or acting on the endothelium. The intracellular signaling molecule endothelin-1 (ET-1), best known as a potent endogenous vasoconstrictor peptide produced by endothelial cells, has an important role in the vasculature and is involved in the development of atherosclerosis. 100 Serum levels of ET-1 are markedly elevated in patients with chronic renal failure, 101,102 and ET-1 is involved in both the development and progression of CKD. 103 Odetti et al. 101 observed a significant positive correlation between pentosidine and ET-1 plasma levels in subjects undergoing chronic hemodialysis (HD). Recently, it has been shown that ET-1 transcription in cultured bovine aortic endothelial cells is controlled by the AGEinducible, redox-sensitive transcription factor NF-kB. 104 AGEs, therefore, play an important role in endothelial dysfunction by (1) decreasing levels of two important endothelium-dependent relaxing factors (NO and PGI2) and (2) increasing endothelial production of the potent vasoconstrictor ET-1. 104 Another important role of the endothelium is its function as a selective barrier between the blood and the surrounding tissues. AGEs have been shown to be associated with increased permeability of the endothelial layer. 105, 106 Arterial Stiffness Arterial stiffening occurs because of loss of compliance of the vessel wall 107, 108 and is an important independent risk factor for cardiovascular mortality in patients with CKD.
CKD not only accelerates the development of atherosclerosis but also, leads to excessive vascular calcification resulting from the inflammation and oxidative stress present in patients with CKD. [109] [110] [111] [112] [113] Vascular calcification is an independent predictor of cardiovascular mortality, 114, 115 and one of its consequences is altered aortic compliance. 116 119 Moreover, lower sRAGE levels were recently associated with carotid plaque calcification. 76 Arterial stiffness has a major role not only in the increase in systolic BP and pulse pressure, but also in the decrease in diastolic BP. This BP alteration leads to left ventricular hypertrophy and abnormal pulse wave velocity (PWV), both of which are apparent at the early stages of CKD. 120 Measurement of PWV, a noninvasive method for assessing arterial wall stiffness related to vascular calcification, 121 is a strong independent predictor of cardiovascular mortality in patients with ESRD. 122, 123 Several studies suggest that AGEs are involved in arterial stiffness. 124 For example, chronic CML ingestion induced RAGE-dependent arterial stiffness in mice. 80 Zhou et al. 125 showed a positive correlation between arterial stiffness and serum pentosidine levels. Moreover, skin autofluorescence (a marker of AGE accumulation) is associated with arterial PWV (and therefore, arterial stiffness) in patients with ESRD. 126 This may be caused by the formation of irreversible crosslinks between the end products and long-lived structural proteins, such as collagen and elastin.
Immune System Dysregulation
The immune system plays an important role in the development and progression of CVD. It has been shown that dysregulation of the immune system contributes to atherosclerosis in patients on HD. 127, 128 Several studies have suggested that AGEs can amplify local immune reactions in the kidney. Other studies in humans have shown that AGE formation and accumulation are partially responsible for the observed immune system dysregulation. Friedlander et al. 129 showed a positive association between serum pentosidine and monocyte activation, which may contribute to elevated complication rates. It has also been shown that decreased AGE intake protects against loss of innate immunity. 130 Diabetic Nephropathy Diabetic nephropathy (DN) is the leading cause of ESRD and the most common indication for RRT. 131 The kidney has an important role in the metabolism of AGEs, because renal proximal tubule cells absorb AGEs from the glomerular filtrate and catabolize them. 132, 133 GFR is negatively correlated with not only serum AGE levels but also, RAGE mRNA expression in PBMCs. 31 Lysozyme that sequesters AGEs reduces the severity of the early manifestations of DN, 56 suggesting that AGEs play an important role in the pathogenesis of DN. 134, 135 Immunohistochemical studies in patients with DN have shown that AGEs accumulate in the mesangium and glomerular capillary wall. 136 Horie et al. 137 showed that patients with advanced DN exhibit enhanced CML accumulation in the expanded mesangial matrix and a thicker glomerular capillary wall in early nodular lesions and arterial walls (relative to the healthy kidney). Similar results were found with the AGE imidazole. 138 Accumulation of AGEs may be caused by both decreased clearance and increased endogenous AGE formation or higher dietary intake. 139 In addition to glomerular accumulation of AGES in DN, the AGE-RAGE interaction can also trigger premature cell senescence, a key process in DN, in response to endoplasmic reticulum stress, partly through p21 signaling activation. 140 
THERAPEUTIC INTERVENTIONS
In view of the many harmful effects of AGEs on cell function, it is essential to develop strategies designed to counteract their effects. Several pharmacologic treatment strategies targeting the AGE-RAGE system have been studied in vitro and in vivo for their potential to prevent AGE formation or local AGE accumulation. 141 These therapeutic compounds can be divided into several classes as a function of their mechanism of action ( Figure 3 , Table 1 ): AGE absorption inhibitors, AGE formation inhibitors, AGE cross-link breakers, RAGE antagonists, and AGE binders, such as sRAGE. Although many compounds are currently being studied, only a few have entered clinical trials, and none have yet been approved for clinical use in patients with CKD.
Decreasing Exogenous Sources of AGEs
Decreased Dietary AGE Intake Dietary AGE content is an important contributor to serum AGE accumulation in patients with CKD. 142 As mentioned above, AGEs are generated during the thermal processing and storage of foods. 4 A recent clinical study in patients with CKD showed that reducing dietary AGEs may lower oxidative stress and inflammation, restore AGER1 levels, and protect against innate immune dysfunction. 130 Dietary restriction is, therefore, an effective, feasible, and economic method to reduce the levels of toxic AGEs and possibly, the associated cardiovascular mortality. 143 
Inhibition of Gastrointestinal Absorption
Another option to reduce the intake of exogenous AGEs is to block or inhibit the gastrointestinal absorption of dietary AGEs. Several compounds have been widely studied, including the spherical carbon adsorbent AST-120 and sevelamer carbonate.
Administration of the oral adsorbent AST-120 before initiating dialysis has been shown to not only improve the survival rate in patients on HD 144, 145 but also, delay the onset of HD in patients with CKD. 146 AST-120 is also associated with a reduction in carotid intima media thickness and arterial stiffness in patients with CKD and without diabetes. 147 However, recent randomized placebo-controlled Evaluating Prevention of Progression In CKD (EPPIC) Trials of AST-120 in CKD did not support the benefit of adding AST-120 to standard therapy. 148 AST-120 has been shown to bind AGE and effectively decrease plasma AGE levels. 144 In a recent animal study, AST-120 was shown to reduce the indoxyl sulfate-induced decrease of Nrf2, 149 which may, therefore, decrease formation of AGEs, such as MG, by increasing Glo-1.
Sevelamer carbonate is a nonabsorbable, noncalcium-based compound frequently used to lower blood phosphorus levels in patients with advanced CKD or ESRD. It has recently been shown that sevelamer can act as a pleiotropic drug by sequestering cytotoxic AGEs in the gut and thus, preventing their uptake. Moreover, sevelamer decreases CML levels, oxidative stress, and inflammation and increases AGER1 expression. [150] [151] [152] [153] The results of a randomized trial in patients on HD showed that sevelamer slows calcification and suppresses pentosidine accumulation. 154 Although longterm clinical studies in patients with CKD have not yet been performed, a short-term comparison of sevelamer with calcium carbonate showed that it lowered serum AGEs in patients on HD. 150 Sirtuin1, an NAD + -dependent histone deacetylase that has anti-inflammatory, antiapoptotic, and antioxidant properties 155 and prevents calcification 156 and endothelial senescence, 157 is decreased by AGEs, such as MG. 158 In a recent clinical study in patients with type 2 diabetes mellitus and stages 2-4 diabetic kidney disease, sevelamer significantly increased antioxidant molecules, such as AGER1, Nrf2, and Sirtuin1, while decreasing prooxidant molecules, such as RAGE and AGEs. 159 Decreasing Endogenous Sources of AGEs Dialysis Several dialysis techniques are currently used, such as HD, hemofiltration (HF), hemodiafiltration, and peritoneal dialysis (PD).
A conventional HD session typically reduces blood AGE levels by #20%, and only low-molecular mass AGEs (,10-kDa AGE peptide) are efficiently removed from the blood. 160 However, this efficiency can be enhanced by increasing the frequency or duration of HD sessions. [161] [162] [163] In HF, molecules are removed from blood by ultrafiltration of a large blood volume under high hydrostatic pressure through a larger-pore size membrane. Membranes with high permeability can, therefore, decrease blood AGEs by up to 60% 164 and up to 80% with high-flux polysulfone. 165, 166 Lin et al. 167 showed that online hemodiafiltration, a combination of both HF and HD, for .6 months in patients with uremia leads to a significant reduction in serum AGE levels. A recent study showed that convective therapies not only effectively cleared uremic toxins but also, decreased levels of inflammatory markers, such as IL-6. 168 PD, an important alternative to HD, also reduces AGEs formation. 169, 170 Advantageously, serum concentrations of AGEs, such as pentosidine, are lower in patients on PD than in patients on HD. 171 However, despite higher levels of AGE excretion in patients on PD, free AGE levels in the PD effluent were elevated because of increased synthesis of free AGEs. Conventional PD fluid contains supraphysiologic concentrations of glucose and glucose degradation Increase of circulating sRAGE and esRAGE levels in the rosiglitazone group; significant reduction of AGEs levels in both groups products (GDPs; generated during sterilization by heating of dialysis fluid) that can increase the formation of AGEs. [172] [173] [174] In patients on PD, high levels of AGE deposition in tissue correlate with glucose exposure. 175 Nonglucose PD solutions or solutions containing low-GDP levels, such as icodextrin, may, therefore, minimize AGE formation. [176] [177] [178] [179] The acidic pH and the hyperosmolality of conventional PD fluid can also damage the peritoneum and consequently, impair its function as a dialyzing membrane.
Other alternatives (such as neutral pH and low-GDP peritoneal solutions 180 ) can also be used to decrease AGE formation during conventional PD. 181 Continuous flow PD is another option that also effectively reduces AGE formation. 170 
Kidney Transplantation
Because AGEs are mainly excreted by the kidneys, serum AGE levels increase with declining kidney function. 182 Kidney transplantation is, therefore, an efficient way of decreasing levels of uremic toxins, including AGEs. Thus, pentosidine levels started to fall within 4 weeks of kidney transplantation and reached normal values after 6 months. 183 Studies showed that kidney transplantation decreases AGE accumulation in tissues, 184, 185 which was assessed by skin autofluorescence, thereby significantly reducing cardiovascular events in recipients of transplants compared with patients on dialysis. 185 
Antioxidants
To decrease endogenous sources of AGEs, several compounds have been developed to attenuate glyoxidation and/or oxidative stress by sequestration of metal ions, reactive dicarbonyl compounds, ROS, and reactive nitrogen species. Thus, the use of antioxidants, such as vitamin E, vitamin A, and lipoic acid, has been studied in vitro to counteract AGE effects. 186 Reactive Dicarbonyl Scavengers Several compounds can trap reactive carbonyl intermediates (AGE precursors) and quench ROS. 187, 188 For example, the strongly nucleophilic Pimagedine (2-aminoguanidine) can scavenge reactive carbonyl intermediates in the Maillard reaction 189, 190 and also, decrease VCAM-1 expression in endothelial cells. 191 Administration of aminoguanidine to patients with ESRD also led to a reduction of circulating LDL levels. 39 The vitamin B6 derivative pyridoxamine (registered as Pyridorin) is a postAmadori inhibitor 192 that traps reactive carbonyl and dicarbonyl compounds derived from Amadori compounds, thereby reducing AGE accumulation. 193, 194 Pyridoxamine also scavenges ROS and chelates metal ions (oxidation catalysts). In diabetic rats, pyridoxamine has been shown to decrease AGE and calcification. 195 Polizzi et al. 196 showed that a combination of vitamins B1 and B6 decreases DNA glycation in patients with DN. However, an 8-week randomized, placebocontrolled study in 50 patients on HD found that the combination of pyridoxine and thiamine had no effect on plasma levels of AGEs and pentosidine. 197 
Renin-Angiotensin System Inhibitors
The renin-angiotensin system plays an important role in the disease processes that leads to DN. 198 Inhibitors of the renin-angiotensin axis can improve glomerular hyperfiltration and are known to decrease the severity of DN in animal and clinical studies. 199 Several angiotensin receptor blockers (including olmesartan, telmisartan, 200, 201 and irbesartan 202 ) have been shown to decrease plasma CML and pentosidine levels in patients on HD 203 and act as antioxidants against AGE. 202 Sebeková et al. 204 found that the angiotensinconverting enzyme inhibitor ramipril significantly decreased levels of fluorescent AGEs but not CML.
Aldose Reductase Inhibitors
Aldose reductase is a multifunctional enzyme that reduces aldehydes, and it is involved in the polyol pathway of AGE formation. Inhibiting aldose reductase, therefore, reduces levels of AGE precursors and decreases AGE accumulation. 205 Administration of the aldose reductase inhibitor eparlestat decreases serum AGE levels in patients with diabetes. 206 
Increasing the Breakdown of AGEs
Agents that break AGE cross-links (reviewed in ref. 207 ) have been shown to improve arterial compliance in humans. 208 Animal and human studies have shown that AGE cross-link breakers, such as ALT-711 and alagebrium, decrease AGE levels 209, 210 and tissue AGEs, 211, 212 reverse their effects, [213] [214] [215] [216] such as aortic stiffness, calcification, 195 and extracellular matrix accumulation, 212 and improve renal function by facilitating urinary excretion of the end products. (Table 1) . This section will focus on emerging therapeutic approaches, such as microRNAs (miRs) and Nrf2 and Glo-1 inducers.
MiRs
There is growing evidence that miRs play a key role in kidney physiology and contribute to both the induction and progression of CKD. 233, 234 miRs are ubiquitously expressed short noncoding RNAs comprising 20-22 nucleotides that regulate key biologic pathways and cellular functions by inhibiting gene expression through post-transcriptional repression of their target mRNAs. 235 For example, miR21 has been shown to be a key therapeutic target for renal injury in a mouse model of type 2 diabetes. 236 Several other miRs have also been implicated in the process of vascular calcification. 111 244 It also decreases hepatic Glo, thereby decreasing serum and hepatic AGEs in MG-treated mice. 245 These widely used plant-derived Nrf2 activators have been shown to be safe with shown health benefits in human subjects, suggesting that they could be beneficial for the treatment of CKD. Bardoxolone methyl, a synthetic Nrf2 activator, has been tested as a therapeutic agent in clinical trials. 246 Despite promising results in phase II trials, a recent study showed that it contributes to higher rates of cardiovascular events in susceptible patients with an increased risk of heart failure at baseline. 247 Additional studies are, therefore, needed to evaluate the safety of these compounds. However, Nrf2 activators seem to be a promising new therapeutic strategy to improve or delay kidney dysfunction.
CONCLUSION
AGEs have been widely described in hyperglycemic conditions, such as diabetes; however, they can also be generated in conditions associated with elevated levels of oxidative stress, such as CKD. 
